Survival Outcomes in Esophageal and Gastric Cancer

Esophageal and gastric cancers remain among the deadliest malignancies worldwide, with five-year survival rates generally below 30 per cent in most settings. Survival outcomes depend heavily on tumour stage at diagnosis, histological subtype and the patient’s overall health status. Multimodal treatment—combining surgery with chemotherapy, radiotherapy or immunotherapy—has gradually improved prognosis, though gains vary by region and health-care infrastructure. Complete surgical resection with negative margins and adequate lymph node clearance offers the best chance of cure, whereas advanced disease often requires palliative approaches aimed at prolonging life and preserving quality of life. Recent advances in perioperative care, refinements in surgical technique and the integration of targeted agents and immune checkpoint inhibitors have begun to shift survival curves, particularly for patients with earlier-stage disease. Meanwhile, variation in access to prompt diagnosis, centre volume and multidisciplinary expertise continues to influence global outcomes. Predictive models that integrate clinical, pathological and molecular data are emerging as tools to estimate individual prognosis and guide follow-up intensity. Public health strategies to reduce diagnostic delays and improve treatment pathways remain critical to advancing long-term survival across diverse populations.

Research from Nature Portfolio

A prospective study conducted in a tertiary referral centre in South Asia examined the impact of delays at various steps—from patient presentation to histopathology reporting and initiation of treatment—on survival in gastric adenocarcinoma. Median intervals ranged from under two weeks for endoscopic assessment to over six weeks for commencement of therapy. Prolonged patient delay prior to initial assessment was associated with shorter median survival, and delays in starting definitive treatment further reduced survival time. The analysis highlighted advanced stage at presentation in over 60 per cent of cases, underscoring the need for system-level interventions to streamline referral pathways, expedite histology reporting and ensure timely access to specialist care to improve outcomes in resource-limited settings.

Survival Outcomes in Esophageal and Gastric Cancer publication trend

The graph below shows the total number of articles in survival outcomes in esophageal and gastric cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Overall survival (OS): The proportion of patients alive at a specified time point after diagnosis or treatment.

Disease-free survival (DFS): The length of time after treatment during which a patient remains free of detectable cancer.

Neoadjuvant therapy: Treatment given before the main intervention (often surgery) to shrink a tumour and improve outcomes.

Pathological complete response (pCR): Absence of viable tumour cells in resected tissue following neoadjuvant treatment.

References

1. Delay in diagnosis to treatment and impact on survival of gastric adenocarcinoma in a low income setting without screening facility. Scientific Reports (2023).
2. Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial. Annals of Oncology (2023).
3. Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study. Cancer Immunology, Immunotherapy (2024).
4. Neoadjuvant chemotherapy in relation to long-term mortality in individuals cured of gastric adenocarcinoma. Gastric Cancer (2024).